Looking back at one year of PANBioRA
During the first year of the project, the PANBioRA team strongly started to work on the different modules the overall PANBioRA system will, in the end, be comprised of. The rating system will allow biomaterial risk assessment at nano-, micro- and miliscale ranges. Beyond the different testing modules, the PANBioRA system includes simulations and multiscale models of cell/tissue biomaterial interactions. From 3rd to 4th December 2018 the PANBioRA M12 partner meeting took place at Epoka University in Tirana, Albania. The event was covered by national news outlets. All partners have presented their work performed during the last six months and had enough time to discuss about the next steps ahead and preparations to be made in order to reach the new set goals. Based on system requirements gathered from users of medical devices at research institutions or hospitals by Dolmen, a first prototype of the PANBioRA device was presented to the consortium. The prototype draft looks really promising and takes into account many requirements in terms of waste management, speed and ease of use. But not only the design development has made significant progress, during the first year of the project the development of modules for cytotoxicity test, mechanical testing and immunoprofiling as well as the microfluidic system integration has advanced considerably as well. At the end of the project the web-based PANBioRA Risk Radar will serve as a horizon scanning tool allowing a broad risk assessment of biomaterials. In order to identify the needs and perspectives for the development and use of an integrated risk governance framework for biomaterials and biomaterial-based products, a survey was developed by Steinbeis Advanced Risk Technologies GmbH. Experts working in the field of biomaterials, implants, medical devices or any other related fields are invited to share their thoughts here: http://bit.ly/2KIt8bU and contribute to the PANBioRA Risk Radar. In terms of the dissemination of first project results and their exploitation, first achievements have been made as well. Steinbeis 2i as responsible partner for these tasks performed the second IPR workshop during the M12 partner meeting in order to identify possible exploitable results and protect knowledge generated within the project. In September the scientific coordinator Protip Medical as well as project partner University of Nottingham and Steinbeis 2i GmbH presented the project at the TERMIS World Congress, one of the major events in the research field of tissue engineering and regenerative medicine, in Kyoto Japan. In the past six months the PANBioRA research partners have released 4 scientific publications in relevant journals such as Frontiers in Bioengineering and Biotechnology or Materials Research Express. A full overview of the project’s publications can be found on the project website: https://www.panbiora.eu/publications/
Countries
Albania, Belgium, Czechia, Germany, Estonia, Spain, Finland, France, Ireland, Serbia, United Kingdom